PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Net income growth 1.25-1.5x TRAW's 34.56%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
3.87%
D&A growth well above TRAW's 3.85%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
17.23%
Deferred tax of 17.23% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-49.98%
Both cut yoy SBC, with TRAW at -1.49%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
93.54%
Slight usage while TRAW is negative at -706.88%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
A yoy AP increase while TRAW is negative at -403.35%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
21.18%
Some yoy usage while TRAW is negative at -24.55%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-49.98%
Both negative yoy, with TRAW at -100.00%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
33.57%
Operating cash flow growth above 1.5x TRAW's 7.10%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-2609.70%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
5.36%
Debt repayment growth of 5.36% while TRAW is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-80.40%
Negative yoy issuance while TRAW is 4432.69%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.